VIAL COX, MARIA CECILIA
Preferred name
VIAL COX, MARIA CECILIA
Main Affiliation
Email
mcvial@udd.cl
ORCID
0000-0002-0399-6144
Scopus Author ID
55553152400
56 results
Now showing 1 - 10 of 56
- Some of the metrics are blocked by yourconsent settings
Item type:Product, Dataset - TGFβ links EBV to multisystem inflammatory syndrome in children(Molecular Signatures Database (MSigDB), 2025); - Some of the metrics are blocked by yourconsent settings
Item type:Product, Dataset - Post-COVID-19 condition: a sex-based analysis of clinical and laboratory trends(2024); ; ; RIVIOTTA, AMY LISA3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A 19 Year Analysis of Small Mammals Associated with Human Hantavirus Cases in Chile(2019)<jats:p>Small mammals present in areas where hantavirus cardiopulmonary syndrome (HCPS) cases had occurred in central and southern Chile were captured and analyzed to evaluate the abundance of rodents and seroprevalence rates of antibodies to Andes orthohantavirus (ANDV). Sampling areas ranged from the Coquimbo to Aysén regions (30–45° S approx.) regions. Ninety-two sites in peridomestic and countryside areas were evaluated in 19 years of sampling. An antibody against ANDV was detected by strip immunoassay in 58 of 1847 specimens captured using Sherman traps. Of the eleven species of rodents sampled, Abrothrix olivacea, Oligoryzomys longicaudatus and Abrothrix hirta were the most frequently trapped. O. longicaudatus had the highest seropositivity rate, and by logistic regression analysis, O. longicaudatus of at least 60 g had 80% or higher probability to be seropositive. Sex, age and wounds were significantly related to seropositivity only for O. longicaudatus. Across administrative regions, the highest seropositivity was found in the El Maule region (34.8–36.2° S), and the highest number of HCPS cases was registered in the Aysén region. Our results highlight the importance of long term and geographically extended studies, particularly for highly fluctuating pathogens and their reservoirs, to understand the implications of the dynamics and transmission of zoonotic diseases in human populations.</jats:p>Scopus© Citations 8 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile(2022); ; ; <jats:p>Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access.</jats:p>6Scopus© Citations 12 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Multicenter Study to Determine the Immune Response to the Vaccine Against SARS COV-2, in Patients With Chronic Kidney Disease on Dialysis and Kidney Transplants(2022); ; ; 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, An international, interlaboratory ring trial confirms the feasibility of an extraction-less “direct” RT-qPCR method for reliable detection of SARS-CoV-2 RNA in clinical samples(2022)Scopus© Citations 2 3 - Some of the metrics are blocked by yourconsent settings
Item type:Product, 11 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Three Decades of Hantavirus Management in Chile: Lessons for Europe(Elsevier BV, 2026-07)1 - Some of the metrics are blocked by yourconsent settings
Item type:Product, 6